In today’s dynamic political landscape, European pharmaceutical companies have a unique opportunity to thrive despite the challenges presented by evolving US policies. While tariffs and cost pressures may cause hesitation, this moment calls for innovation and bold strategies. Are these obstacles a chance for growth, or merely an excuse to hold back?